Efficacy of 0.05% cyclosporine combined with olopatadine hydrochlorideeye drops for moderate-to-severe pediatric vernal keratoconjunctivitis
10.3980/j.issn.1672-5123.2026.9.26
- VernacularTitle:0.05%环孢素联合盐酸奥洛他定滴眼液治疗中重度儿童春季角结膜炎
- Author:
Jingwei LI
1
;
Lan YU
1
;
Qiaoqiao DONG
1
;
Jiao QIN
1
Author Information
1. Aier Eye Hospital of Wuhan University, Wuhan 430000, Hubei Province,China
- Publication Type:Journal Article
- Keywords:
vernal keratoconjunctivitis;
moderate-to-severe;
olopatadine hydrochloride;
0.05% cyclosporine;
therapeutic efficacy
- From:
International Eye Science
2026;26(9):1661-1664
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To observe the therapeutic efficacy of 0.05% cyclosporine combined with olopatadine hydrochlorideeye drops in the treatment of moderate-to-severe pediatric vernal keratoconjunctivitis.METHODS:A prospective randomized controlled study was conducted. Patients with moderate-to-severe pediatric vernal keratoconjunctivitis admitted to the hospital from January to December 2023 were collected and divided into two groups according to the random number table method: the observation group was treated with olopatadine combined with 0.05% cyclosporine hydrochloride eye drops [1 drop per time of 0.05% cyclosporine eye drops(II), four times a day; 1 drop per time of olopatadine hydrochloric eye drops, twice a day]; the control group was treated with sodium hyaluronate combined with olopatadine hydrochloride eye drops(1 drop per time of sodium hyaluronate eye drops, four times a day; 1 drop per time of olopatadine hydrochloric eye drops, twice a day; ). The treatment lasted for 12 wk. The changes in symptom and sign scores of the two groups before treatment, and at 4, 8, and 12 wk after treatment were compared.RESULTS:Totally 42 children(84 eyes)with moderate-to-severe vernal keratoconjunctivitis were enrolled. All patients returned for follow-up visits on time, with no lossto follow-up. The observation group consisted of 21 patients(42 eyes), with 15 males and 6 females, and the average age was 9.00±3.02 y. The control group consisted of 21 patients(42 eyes), with 18 males and 3 females, and the average age was 9.38±3.28 y(all P>0.05). At 4, 8, and 12 wk after treatment, the ocular symptom and sign scores of both groups decreased compared to those before treatment(all P<0.05), and the decrease in the observation group was more significant than that in the control group(P<0.05). During the treatment period, one patient in the observation group experienced a transient mild ocular irritation at the beginning of medication, which was not treated specially and relieved spontaneously after 3 d. No severe adverse reactions such as elevated intraocular pressure or corneal infection occurred in either group during the treatment period.CONCLUSION:The combination of 0.05% cyclosporine and olopatadine hydrochlorideeye drops significantly alleviates the clinical symptoms and signs of moderate-to-severe vernal keratoconjunctivitis, showing favorable safety and efficacy in the treatment of moderate-to-severe pediatric vernal keratoconjunctivitis.
